A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 864-866

  Yip, D ^a   Karapetis, C ^a   Strickland, A H ^a   Steer, C ^a   Holford, C ^b   Knight, Sidonie ^b   Harper, P ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 fluorouracil; Eniluracil; Gastrointestinal cancer; Maximum tolerated dose intensity; Oxaliplatin

Indexed keywords

5 ETHYNYLURACIL; CISPLATIN DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DYSESTHESIA; FEMALE; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

EID: 0038350310     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg254     Document Type: Article

References (15)

1. Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001; 84: 1-7.
2. Spector T, Harrington JA, Porter DJT. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993; 46: 2243-2248.
3. Baker SD, Khor SP, Adjei AA et al. Pharmacokinetic, oral bioavailability and safety study of fluorouracil in patients treatment with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085-3096.
4. Baker SD, Diasio RB, O'Reilly S et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000; 18: 915-926.
5. Mani S, Hochster H, Beck T et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2000; 18: 2894-2901.
6. Wilking N, Glimelius B, Schueller J et al. Promising early results of oral 5-fluorouracil plus eniluracil (776C85) in patients with advanced adenocarcinoma of the pancreas. Ann Oncol 1998; 9: 46-47.
7. Bleiberg H, DeGramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998; 25: 32-39.
8. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
9. Louvet C, Andre T, Tiguad J et al. Phase II trial of oxaliplatin (OXA) in combination with 5-FU and folinic acid (FA) - FOLFOX6 regime - as first-line treatment for advanced or metastatic gastric cancer (A/MGC) patients. Proc Am Soc Clin Oncol 2000; 19: 265a (Abstr 1031).
10. Evans TRJ, Lofts FJ, Mansi JL. A phase II study of continuous infusion 5-fluorouracil with cisplatin plus epirubicin in operable pancreatic cancer. Br J Cancer 1996; 73: 1260-1264.
11. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
12. Schilsky RL, Hohneker J, Ratain MJ et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998; 16: 1450-1457.
13. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647-662.
14. van Cutsem E, Sorensen J, Cassidy J et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20: 131a (Abstr 522).
15. Schilsky R, Levin J, West W et al. Randomized, open-label, phase III study of a 28 day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002; 20: 1519-1526.